Bailard, Inc. Avadel Pharmaceuticals PLC Transaction History

Bailard, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 10, 2020	SELL	$5.02 - $8.98 $1.47 Million - $2.63 Million	-293,000 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$7.25 - $11.75 $1.47 Million - $2.39 Million	203,000 Added 225.56%	293,000 $2.37 Million
Q1 2020 Apr 16, 2020	BUY	$4.06 - $10.64 $365,399 - $957,600	90,000 New	90,000 $715,000
Q1 2018 May 07, 2018	SELL	$6.76 - $11.7 $953,160 - $1.65 Million	-141,000 Closed	0 $0
Q1 2017 Jan 29, 2018	BUY	N/A	141,000	141,000 $1.37 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $477M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.